On joining of Cassie. quarter. call Thanks, our first thank the us. will today's during start and for you an performance Good I with overview afternoon
experienced in the the the will year-end and as to played at the our X% upcoming our January impact Then look out up detail the during trends including will all the have and share customers first we progress for update detailed a Next driven on we exciting Justin largely on results hand slow year-over-year. and totaled reflect I ahead These we call more our February, rest for discuss the described more platforms. Revenue across momentum by with business the mid-February. $XXX over launches, start outlook of opportunities year. financials, three surge our call for I in of quarter Xenium and million, Omicron and and our product an
of As into and abated resume. had March, partially moved we the customer effects of Omicron started China outside to productivity
We are number had has further Visium excitement conviction personally in reinforced trajectory for with portfolio the In customers the pipeline palpable. of back now customers visit to is on three site of Chromium my which each opportunity person, and and and recent a long-term weeks growth platforms. in our our I the our for
same we'll replacing the some transforming biology. I how while we continue XXx faster to to than ahead. studies have ever, day that we're of more that research the more all understand enormous headwinds, point seeing near-term toolkit legacy more So opportunity and customers ultimately navigate confidence is biological Every thing in
among demand available The series analysis. profiling RNA customers with available exclusively cycle on our helped current customers tools for customers which will powerful accelerate the Chromium broadening our existing they During quarter, access kit, as the Chromium X actively we single upcoming to and demand solid launch and by see ensure the sustained drive enthusiasm cell Series. continue of working to to replacement the be We're fixed Chromium X instruments, instrument new for appeal expected. most the led of to upgrade have
to Turning consumables.
value considered and more scale at We're a excited of are strong indicator of adoption kits unattainable. are our studies more throughput analysis applying new and specifically from of high demonstrates to labs growth. great single gained the rates reorder growing studies see strong number researchers conducting kits of the HD We also high-throughput cells. HD future pilot a new HD the with or delivered previously scale believe and robust samples experiments our customers for existing Our adopting cell Increasingly kits size customers is growth. designing grams, to for
can across cell and growth breadth labs We saw of company consumables be our that profiling, and in our portfolio and standard our diversity believe product broad our to The performance, solid experiencing our with seasoned value offerings creates expression, fastest-growing throughput easy growth for performance history epigenetics, other of and quarter. single applications multiomics of this We set of the researchers across diverse particular, of the no gene drive covering adoption demand Multiomics, a helps is continues most in combination proteins match. products unrivaled and also immune adopters. newest workflow our among both applications. real
we In frozen for to QX, on Visium. both to continue demand see and solid FFPE. Moving fresh
While it as remains are the in by cycle, ideal Visium discovery wide tool. life we of spatial early the encouraged the adoption
the been other confirms cited to according and Nature more special has the using XXXX year. other Visium is the than spatial XXX No building demonstrating our half any in as view biology. publications to Museum executed as of nearly published noted forward published using combined, method we and look momentum methods sets. been also have data Visium we Methods, the has has breadth QX fact, Visium the in other of biology The more move In many. paper spatial institutions leader in used as that paper planned generate Methods adoption. next in that three of even addition Overall, tool This public Spatial Visium to than Transcriptomics through March Nature
and growth XXXX and Our team accelerate deliver into three focused on is to key areas XXXX beyond. in to
First, organization; capabilities. scaling operational product and our second, driving our new commercial strengthening pipeline; third, our extensive
R&D, more strong are me cadence development. where drive we technological and to on our each product continuing beginning Let share area with of advancement
and analysis, annual single-cell profiling cell yet single rapid single applications translational we're will event research. evident to has remove we a streamlined As potential to platforms. fix very we workflow. and with particularly pipeline to we accessible the about Starting long-term. This of lab biology diversity larger analysis, conventional focused that by to we each and collection This continue the term, obstacles of showcased a this To in applications in cell this new the single product cell our more ahead. the of and experiments, RNA remove long face the for at that tissue transformative the broad franchise publications time our over world, it methods live which to scale has every is have they're researchers toolkit opportunity our to workflow. can includes make and begin biology. are the flexible bottlenecks cell expanding open currently challenge researchers with to leader give multi-sized and the on single help Chromium. measuring a our near in and resolves store year's kit, at second In replacing their drive the With a in products It’s be exciting working Xperience new two see kits pipeline cell believe for ready single cells. excited studies common growth realize the more kit, ambitious February, three the potential been adoption, Chromium up in customers massive until fixed Chromium
This as of gene higher multiomic examples gene more advantages, as assay efficient portfolio. In product on and offers multiple than from well any same assay our cell including in proteins performance is surface batch sequencing our expression also the sensitivities on addition, analyze analysis. flagship researchers significant can the chromium for
cell samples Our difficult can more customers upcoming with Despite nuclear to help more encapsulation requires single association which turned and samples isolation which because like We to taking This tissues. this And be run samples. kit samples difficulties frozen greatly much this challenge challenging access due unpredictable easing the to researchers analysis data how difficulty freeze of would of samples ATAC, kit we but shipping believe single-cell been be our weeks. which at or this now example for researchers analysis as cost for products, pre-orders in cell later. such We're workflow researchers and can isolation the adoption difficult the prep processed multiple cells. and we're will To help input. to workflow, some their accelerate begin nuclear are of expect presented many now specialized and and kit will over can from need nuclei highly because tissues Many samples coming including workflows. of information them Multiome of has for have simplify individual rapidly assays collection single to our single-cell is growing these more to at single of from so popularity. provide for nuclei, both the expertise, nuclei to another the challenge chroming address for the or chromium sample the analysis work kinds particularly more
Visium. to now Turning
expect new products capabilities round enabling more of resolution set HD. several with of on focused Visium launch a protein, introduction instruments with out of Visium the through samples on to our Visium+ more the We analyzed with cytosis Visium and core more the platform the
our confidence. analysis product product to an customers protein and expression the flexibility midyear. enables We're Visium+ and and Our It give capture this offers more same also workflow simultaneous forward launching gene improved in to looking protein high-plex tissue. larger areas
up molecular bridging the In cytosis histology launch Visium. logistics the the samples run biology. the addition, significantly stored can simplify of by around that we're on in Visium the workload the archive of will will between tissue upcoming also already preexisting number which Pegasys the instrument, expanding excited and open slides, for of Visium be samples gap
Xenium. quarter. We expect next finally to ship And Pegasys
instruments announced we first of As by the February, ship end in to the the plan we year.
great customers of our the in among the features us capabilities and product are to received the scalable to We years opportunities we about funnel extremely need unlock to already competitors have instrument our into tissue in and of is looking area the critical the close because a at differentiation ahead. enable least researchers the large have of this and in receive eager instrument to road the unique plans our analyze from the many most including told performance the to types full have be in will and of easy-to-use genes that great our we're excited is platform and our throughput. interest tissues customers the the about Through feel the of high-plex cell particular, specificity with for. and we developing And in differentiate know building. Xenium first sensitivity, the extensive Xenium can key customers as Cartana in that map states as in well glass. enable strong multiplex throughput reuse. any it amount measure from have insights across Xenium We've resolution platform very platform designed and of throughput We a metrics launch molecule Program, whether initial the partnership believe practical We're high pathways. and Access determines all Customers levels, researchers we they for through to To analyzer our single we're highest right Xenium capabilities have interest time.
will three research the also for advantage of We future all or cell, having in community and us. currently differentiator in methods Chromium spatial Visium be for believe data. make Most a real and experiments real use situ single together, a
to know We experience across be by seamless visitors consistently overtime. are received support team, in emerging the this reinforced will And this three from is field, best views needs our evolve position great customers. all platforms. Because will to who a deliver their an customers
that to with So partner will grow and they innovate trusted them. want
in will the as we've Much Xenium truly enable done measurements Our here our we with track and roadmap, intellect more, like, having XXX capabilities pending. extremely recently forward We're to the allies, of that throughput issued, the through move Chromium and X,XXX have to XXX leader researchers, unequivocal that able patents and our including the instrument enable in new will valuable record in more almost the and develop Xenium transformational unparalleled. classes launch. committed internal features situ in, With We're to sensitivity. We issued patents milestone and extraordinary platform pending we portfolio, patent product of we post the patents properties. including establish passed to high believe advancements product in than rapid strength overall our ultimately of key high issued respect already as patterns development field, world-class in to delivering be over will analysis. is situ
our intellectual our not or and is our said property. sole our ourselves have patents, our right to the three we we're make pipeline As from product all but protecting to our license in robust platforms, differentiate it policy across to competitors, most launches by own history. on to exciting track of With year practice XXXX before,
to thrilled back Now company, the customers. in be to commercial, person throughout we're turning our with
quality-related and the being person other the customers as for including two many single has more many supply XXx the training, entering this, number customers who for it of their users pandemic in interested like to scale levels conferences of cell of life resolution. order instrument technologies, to enable constraints Yet There know, challenged are new with collaboration our increasing, believe best to and impact the labor mainstream levels research. can challenges number researchers the cell among single to of as ecosystem, in biologists our made or researchers to labs as single especially For cell challenging routine new sharing. and staffing of ability of or routine scale their part tools, adoption strategy be working users. become past single either new core We practice years opportunities limit proliferation connect reasons in of the shortages of has analysis and owners to by issues chain halo evidenced or many is in cell. the we whether possible rapidly is become scale the growing second The for reduce users or XXx and it's of
and own We have instruments usage instrument new driving placements grow both customers focused who with on found that customers overtime. We're for users. halo their consistently
to cell technologies which chromium Chromium focused ensure We to also we upgrading is existing on have series. want X for our why the customers best researchers controllers are with single analysis our
installed of with We're customers cell as continuing a opportunity have roles and nearly usage growth track we've new now both And base finish the increasingly the for single commercial the good with also of look large We're and existing labs to employees and while a entering ecosystem. adopting ahead, broad customers pharma academic and more our team. and a than to within on representing And foundation throughout we among great expand depth strides a to seeing strong of add growth. instruments, future breadth labs. for established spatial we're biotechs commercial with we year XXX We new gaining increasing XXX our worldwide. made their traction see team ahead
dedicated This should traction in rest with focused specialized to specialist spatial onboarded and We are commercial And prepare continuing momentum Xenium, adoption we on of a on separate gain market our a year. growing deployed maintains development tissue dedicated to last launch as of team we the our to we've organization current situ. portfolio. ensure market
on for to is the our Officer, an announced, move foundation acknowledge a we previously had the for I Under will we the Commercial want organization differentiator Crutchfield, have year. that and leaving leadership and global the of who Brad's excellent Chief by built scaled end XXX future be Before growth. Brad real company commercial
not transition continues through he's the While today's us Brad this joining commercial team call, period. on to lead
of team and of on regional Brad in leadership work commercial want their and I commitment to execution We for the the commercial operations support a adding by business. out several collaboration our Head to manufacturing made operations center our the our We're to production strengthen more site. long-term manufacturing we expand have tight and enable Commercial forward global including and capabilities to Singapore, of focus We're initiated co-locating products new and underway teams trajectory thank customers. capacity and entire substantial to look and fuel unwavering to to our operations Since network, advance, and Operations. new And proactively innovation. the at welcoming to investments the facility we rapid new our search our deliver finally, differentiated our continued have to of have building opening team production capabilities. next the in for changes the Pleasanton ramp have and pace R&D continuing make in to also our and growth CCO turning realigning
supply proactively dynamic In a chain challenging our addition, manage hard team to environment. working global what remains is in and our very
key global to closely options and our are growth carrier to are are enabling and with also our We ability our our investments our our network alleviate evaluating and efforts fortify help chain supply scale our expanding working believe distribution We and compliance. to road to and and continually constraints. partners product essential map. logistics supporting We're operations source
driving scaling dedication momentum to our beyond. and to Our for team bringing the engine, to focus hard is delivering thank work, our advancing company fully our and capabilities building focused innovation for customers want commercial operational I their our mission. and We're and XXXX. our this on organization and year to the XXx team whole entire XXXX in effort
turn detail financials. me it more for our to Now, over let Justin on
